deferasirox has been researched along with Hemoglobinopathies in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 3 (60.00) | 2.80 |
| Authors | Studies |
|---|---|
| Borella, E; Della Pasqua, O; Magni, P; Oosterholt, S | 1 |
| Ahmed, J; Moeed, A; Naeem, U; Rais, H; Saleem, A; Shuja, SH; Waqar, E | 1 |
| Bejaoui, M; Bonifazi, D; Ceci, A; Christou, S; Cosmi, C; Cuccia, L; Del Vecchio, GC; Della Pasqua, O; El-Beshlawy, A; Felisi, M; Filosa, A; Hassab, H; Kattamis, A; Kreka, M; Maggio, A; Origa, R; Putti, MC; Reggiardo, G; Sherief, L; Spino, M; Telfer, P; Tempesta, B; Tricta, F; Tsang, YC; Vitrano, A; Zaka, A | 1 |
| D'Ascola, DG; Fragomeno, C; Roccabruna, E | 1 |
| Badcock, CA; Bowden, DK; Brown, G; Gervasio, OL; Grigg, A; Ho, PJ; Marlton, P; St Pierre, T; Tay, L; Teo, J; Traficante, R | 1 |
1 review(s) available for deferasirox and Hemoglobinopathies
| Article | Year |
|---|---|
No difference in myocardial iron concentration and serum ferritin with deferasirox and deferiprone in pediatric patients with hemoglobinopathies: A systematic review and meta-analysis.
Topics: Benzoates; beta-Thalassemia; Child; Deferasirox; Deferiprone; Ferritins; Hemoglobinopathies; Humans; Iron; Iron Chelating Agents; Iron Overload; Pyridones; Triazoles | 2023 |
2 trial(s) available for deferasirox and Hemoglobinopathies
| Article | Year |
|---|---|
Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial.
Topics: Administration, Oral; Adolescent; Agranulocytosis; Albania; Anemia, Sickle Cell; beta-Thalassemia; Cardiac Imaging Techniques; Child; Child, Preschool; Cyprus; Deferasirox; Deferiprone; Egypt; Erythrocyte Transfusion; Female; Ferritins; Greece; Hemoglobinopathies; Humans; Infant; Iron Chelating Agents; Iron Overload; Italy; Magnetic Resonance Imaging; Male; Patient Compliance; Treatment Outcome; Tunisia; United Kingdom; Urologic Diseases | 2020 |
Cardiac iron load and function in transfused patients treated with deferasirox (the MILE study).
Topics: Adolescent; Adult; Aged; Benzoates; Blood Transfusion; Chelation Therapy; Deferasirox; Female; Ferritins; Heart Function Tests; Hemoglobinopathies; Humans; Iron; Iron Chelating Agents; Iron Overload; Magnetic Resonance Imaging; Male; Middle Aged; Myocardium; Transfusion Reaction; Treatment Outcome; Triazoles; Young Adult | 2017 |
2 other study(ies) available for deferasirox and Hemoglobinopathies
| Article | Year |
|---|---|
Characterisation of individual ferritin response in patients receiving chelation therapy.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Ferritins; Hemoglobinopathies; Humans; Iron; Iron Chelating Agents; Pyridones; Triazoles | 2022 |
Effect of deferasirox on iron overload in patients with transfusion-dependent haemoglobinopathies.
Topics: Adolescent; Adult; Benzoates; Child; Deferasirox; Female; Ferritins; Hemoglobinopathies; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Male; Middle Aged; Myocardium; Retrospective Studies; Stroke Volume; Transfusion Reaction; Treatment Outcome; Triazoles; Ventricular Function, Left; Young Adult | 2015 |